A comparison of concomitant administration of Azithromycin and Cefixime to Azithromycin alone in the treatment of Typhoid - ACT South Asia

The University of Oxford0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•1. A history of fever at presentation for 72 hours or more and a documented fever (37.5 degrees Celsius or more(axillary) or 38degree Celsius or more(oral))
•2. Age 2 years or more (and weight 10kg and more) to 65 years
•3.No clear focus of infection on initial clinical evaluation
•4. Malaria RDT negative; dengue NS1 RDT negative; scrub typhus RDT negative; CRP rapid test 10 mg/L or more
•5. Able to take oral treatment
•6. Able to attend for follow-up and can be contacted by telephone
•7. Written fully informed consent to participate in the study including assent for children in addition to parental/legal guardian consent.

•1. History of fever for >14 days
•2. Pregnant or positive pregnancy test or breast-feeding
•3. Presence of clinical symptoms or signs indicating a focal infection such as pneumonia; urinary infection, meningitis, eschar
•4. Obtundation, hemodynamic shock, visible jaundice, gastrointestinal bleeding or any signs of severe disease that may require immediate hospitalization
•5. Being treated for TB or HIV or severe acute malnutrition
•6. Patients with cardiac disease
•7. Patient requiring intravenous antibiotics for any reason
•8. Previous history of hypersensitivity to any of the treatment options
•9. Either of the trial drugs are contraindicated for any reason (e.g. drug interactions)
•10. Has received azithromycin or cefixime in the last five days
•11. Receiving another antimicrobial and responding clinically to the treatment as judged by the attending clinician.
•12. Being on another drug ( for example certain kinds of antidepressants, or anticonvulsants) that may also cause prolonged QT interval
•13. PCR positive for Co-Vid 19 before or after randomization

发起方